Dey L.P. issued new U.S. patents for Perforomist inhalation solution
A study by scientists in New Zealand say craving something sweet like a biscuit or piece of chocolate could be a response to an addiction. According to Dr. Simon Thornley from Auckland’s Regional Public Health Service the reason unhealthy sugar and fat laden foods are being consumed is because they are addictive and could be
Full Post: Food-addiction blamed for obesity
Mylan Inc. has announced that its subsidiary Dey L.P. has been issued several additional U.S. patents protecting the company’s Perforomist(R) Inhalation Solution, a chronic obstructive pulmonary disease (COPD) treatment.
U.S. Patent No. 7,462,645 was issued Dec. 9, 2008, and is directed to treatment through the administration of a ready-to-use, storage stable composition of formoterol. This patent covers Dey’s Perforomist(R) Solution, and its term extends until June 22, 2021. The patent will be listed in the “Orange Book,” giving Dey four Orange Book-listed patents covering Perforomist Solution.
U.S. Patent Nos. 7,465,756 and 7,473,710 were issued Dec. 16, 2008, and Jan. 6, 2009, respectively. These patents are directed to compositions of “R-formoterol,” a specific form of the formoterol molecule, and their use.
In addition, Dey has received a “Notice of Allowance” on yet another patent also directed to the use of R-formoterol. This patent is expected to issue shortly. Upon its issuance, Dey will possess seven patents directed to compositions of formoterol, R-formoterol and/or their uses.
Mylan’s Vice Chairman and CEO Robert J. Coury stated: “We are very pleased with the recent issuance of these additional patents, which we believe only further bolster Dey’s already strong intellectual property portfolio, and we will continue to aggressively protect and assert Dey’s IP rights. Dey is currently pursuing a patent infringement lawsuit against Sepracor relating to its Brovana(R) product.”
Dey also has additional pending U.S. patent applications directed to formoterol-containing compositions and their use in the treatment of respiratory conditions.
Peregrine Pharmaceuticals, Inc. has announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number No. 7,455,833, which includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids. The aminophospholipid family of phospholipids, including phosphatidylserine (PS), represents a novel target for anti-viral therapies. The new patent follows publication this week
Full Post: Peregrine Pharmaceuticals awarded U.S. patent for anti-viral applications of phospholipid-targeting antibodies
Mylan Inc. has announced that it and its subsidiary, Mylan Pharmaceuticals Inc., have entered into a settlement agreement with Novartis Pharmaceuticals Corp., Novartis Corp. and Novartis International AG related to Letrozole Tablets, the generic version of Novartis’ Femara. Mylan’s Vice Chairman and CEO Robert J. Coury commented: “We are very pleased to have reached this
Full Post: Mylan settles with Novartis on Femara
Oncolytics Biotech Inc. has announced that it has been granted its 31st U.S. Patent, # 7,476,382, entitled “Reovirus for the Treatment of Neoplasia.” The patent includes claims to pharmaceutical compositions containing reovirus. “This U.S. patent expands and strengthens our proprietary position for REOLYSIN(R),” said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics. “The
Full Post: Oncolytics Biotech issued new U.S. patent “Reovirus for the Treatment of Neoplasia”
Genta Incorporated has announced that two new patents related to the Company’s franchise in gallium-containing products have issued in the United States. Applications similar to these patents are pending worldwide, and several additional applications that address other compositions and uses have been filed in the U.S. and other territories. These patents and filings provide for
Full Post: Genta Incorporated issued two key U.S. patents for gallium products franchise
Bavarian Nordic owns several United States patents relating to an attenuated strain of the company’s core technology, MVA-BN(R), which is the basis for its smallpox vaccine, IMVAMUNE(R). MVA-BN(R) also holds promise as a vector for delivering recombinant vaccines. Bavarian Nordic has asserted three US patents as a basis for its infringement action. The claim in
Full Post: Bavarian Nordic’s patent infringement suit against Oxford BioMedica